<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660528</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001263</org_study_id>
    <nct_id>NCT02660528</nct_id>
  </id_info>
  <brief_title>Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder</brief_title>
  <official_title>Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder: An Open-Label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed study sets out to examine the antidepressant effects of tocilizumab among&#xD;
      patients with treatment-refractory major depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As the understanding of the complex relationship between pro-inflammatory cytokines&#xD;
      (specifically interleukin-6 [IL-6]) and depression symptoms becomes clearer, clinical trials&#xD;
      to evaluate effective and novel treatments are needed. As there have been no published&#xD;
      tocilizumab trials among patients with major depression, this pilot study will adopt a&#xD;
      single-arm, open-label design. Due to the notion that inflammatory cytokines may play a role&#xD;
      in a sub-type of depression, this study will recruit patients with treatment refractory major&#xD;
      depressive disorder, for whom established depression treatments have not been effective. In&#xD;
      conducting this trial, the investigators seek to examine the potential role of tocilizumab as&#xD;
      an augmentation agent, with the hypothesis that it could reduce depression symptomatology in&#xD;
      patients with major depression who have not experienced symptom reduction through more&#xD;
      traditional antidepressant therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study staff change.&#xD;
  </why_stopped>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change on Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>Baseline to 8 Weeks</time_frame>
    <description>Absolute change on Hamilton Depression Rating Scale (HDRS) score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving Remission (HDRS Score &lt; 7)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Proportion of Subjects with an HDRS score &lt; 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving Response (HDRS Score Decreased &gt;50% From Baseline)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Proportion of Subjects with an HDRS score decreased &gt;50% from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab 162 mg sc q2weeks x 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Subcutaneous tocilizumab</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of major depressive episode&#xD;
&#xD;
          -  Hamilton Depression Rating Scale (HDRS) score of &gt;20&#xD;
&#xD;
          -  In treatment for depression for a minimum of 8 weeks&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Active drug or alcohol disorder in the last three months&#xD;
&#xD;
          -  History of psychosis, mania or hypomania&#xD;
&#xD;
          -  Acute suicide or homicide risk&#xD;
&#xD;
          -  History of liver disease including HCV and HBV&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  History of heart disease or a heart attack&#xD;
&#xD;
          -  Active or latent tuberculosis, a history of a positive tuberculosis test, or having&#xD;
             received the Bacillus Calmette-Guérin (BCG) vaccine&#xD;
&#xD;
          -  Epilepsy or a history of seizures&#xD;
&#xD;
          -  Abnormal thyroid-stimulating hormone (TSH &lt;0.4 or &gt;5.0mlU/L)&#xD;
&#xD;
          -  Abnormal liver function tests on screening (ALT&gt;50 U/L or AST&gt;50 U/L)&#xD;
&#xD;
          -  Low absolute neutrophil count (ANC) on screening (&lt;4000/mm3&#xD;
&#xD;
          -  Abnormal white blood cell count (&lt;4,500 or &gt; 10,000mcL)&#xD;
&#xD;
          -  Low platelet count on screening (&lt;150,000/mm3&#xD;
&#xD;
          -  Patients with an active or recent infection, for example cellulitis, bacteremia,&#xD;
             pneumonia, and pyelonephritis.&#xD;
&#xD;
          -  Recent exposure to uncommon infections (e.g. histoplasmosis, blastomycosis,&#xD;
             coccidiomycosis) through recent travel to the Ohio and Mississippi River Valleys and&#xD;
             the Southwest&#xD;
&#xD;
          -  Pregnant women, breastfeeding women or women of child-bearing age not using&#xD;
             contraception&#xD;
&#xD;
          -  History of or current autoimmune disease, including multiple sclerosis and&#xD;
             inflammatory bowel disease&#xD;
&#xD;
          -  Diagnosis of chronic fatigue syndrome&#xD;
&#xD;
          -  Temperature greater than 100.3F at the screening visit or any subsequent visits&#xD;
&#xD;
          -  Dyslipidemia&#xD;
&#xD;
          -  Currently taking oral steroids&#xD;
&#xD;
          -  Currently taking statins&#xD;
&#xD;
          -  Chronic aspirin or NSAID takers&#xD;
&#xD;
          -  Currently taking any immunomodulating medications&#xD;
&#xD;
          -  Inability to consent due to cognitive impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Harder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Moss SJ, Brandon NJ. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry. 2012 Dec 4;2:e199. doi: 10.1038/tp.2012.120.</citation>
    <PMID>23212583</PMID>
  </reference>
  <reference>
    <citation>Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015 Aug 15;182:106-14. doi: 10.1016/j.jad.2015.04.044. Epub 2015 May 5.</citation>
    <PMID>25985379</PMID>
  </reference>
  <reference>
    <citation>Fonseka TM, McIntyre RS, Soczynska JK, Kennedy SH. Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opin Investig Drugs. 2015 Apr;24(4):459-75. doi: 10.1517/13543784.2014.998334. Epub 2015 Jan 14. Review.</citation>
    <PMID>25585966</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <results_first_submitted>September 17, 2020</results_first_submitted>
  <results_first_submitted_qc>October 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jessica Harder</investigator_full_name>
    <investigator_title>Associate Psychiatrist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02660528/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No participants were assigned to treatment arms because none of the participants were eligible to continue the study after screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tocilizumab</title>
          <description>Tocilizumab 162 mg sc q2weeks x 4 doses&#xD;
Tocilizumab: Subcutaneous tocilizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Demographics</title>
          <description>Demographics of screened subjects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.67" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change on Hamilton Depression Rating Scale (HDRS)</title>
        <description>Absolute change on Hamilton Depression Rating Scale (HDRS) score</description>
        <time_frame>Baseline to 8 Weeks</time_frame>
        <population>No data was collected for the study outcome measures because none of the participants were eligible to continue the study after screening.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 162 mg sc q2weeks x 4 doses&#xD;
Tocilizumab: Subcutaneous tocilizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change on Hamilton Depression Rating Scale (HDRS)</title>
          <description>Absolute change on Hamilton Depression Rating Scale (HDRS) score</description>
          <population>No data was collected for the study outcome measures because none of the participants were eligible to continue the study after screening.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving Remission (HDRS Score &lt; 7)</title>
        <description>Proportion of Subjects with an HDRS score &lt; 7</description>
        <time_frame>8 Weeks</time_frame>
        <population>No data was collected for the study outcome measures because none of the participants were eligible to continue the study after screening.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 162 mg sc q2weeks x 4 doses&#xD;
Tocilizumab: Subcutaneous tocilizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving Remission (HDRS Score &lt; 7)</title>
          <description>Proportion of Subjects with an HDRS score &lt; 7</description>
          <population>No data was collected for the study outcome measures because none of the participants were eligible to continue the study after screening.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving Response (HDRS Score Decreased &gt;50% From Baseline)</title>
        <description>Proportion of Subjects with an HDRS score decreased &gt;50% from baseline</description>
        <time_frame>8 Weeks</time_frame>
        <population>No data was collected for the study outcome measures because none of the participants were eligible to continue the study after screening.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 162 mg sc q2weeks x 4 doses&#xD;
Tocilizumab: Subcutaneous tocilizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving Response (HDRS Score Decreased &gt;50% From Baseline)</title>
          <description>Proportion of Subjects with an HDRS score decreased &gt;50% from baseline</description>
          <population>No data was collected for the study outcome measures because none of the participants were eligible to continue the study after screening.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were not collected as no participants were eligible to participate in the study after screening.</time_frame>
      <desc>No adverse event information was recorded because no participants were eligible to continue with the study after screening.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tocilizumab</title>
          <description>Tocilizumab 162 mg sc q2weeks x 4 doses&#xD;
Tocilizumab: Subcutaneous tocilizumab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jessica Harder</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-525-7919</phone>
      <email>jaharder@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

